From Citizendium
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and subject to a disclaimer.
IUPAC name: see below
Synonyms: see Chemistry
Formula: C30H25F10NO3

 Uses: cholesterol regulation

 Properties: see below

 Hazards: see below

Mass (g/mol): CAS #:
637.51 875446-37-0

In health care, anacetrapib (anacet'rapib) is an oxazolidinone-based medication that is a cholesteryl ester transfer protein inhibitor that raises HDL cholesterol and reduces LDL cholesterol.[1]

Anacetrapib is related to torcetrapib.[2]

Chemistry and Mechanism of Action

The chemical name of anacetrapib, distributed by Merck, is 2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one. It has a formula weight of 637.51 g/mol and its CAS registration number is 875446-37-0. Anacetrapib is an inhibitor of cholesteryl ester transfer protein (CETP), a key protein involved in reverse cholesterol transport, and its use increases high-density lipoprotein cholesterol (HDL). Other CETP inhibitors include dalcetrapib and torcetrapib. [3],[4]


  1. Anonymous (2022), Anacetrapib (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM et al. (2010). "Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.". N Engl J Med. DOI:10.1056/NEJMoa1009744. PMID 21082868. Research Blogging.
  3. Gurfinkel R, Joy TR (2010). "Anacetrapib: Hope for CETP Inhibitors". Cardiovasc Ther. PMID 21082868. [e]
  4. Mason D (2009). "Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclrerosis". Curr Opin Investig Drugs 10 (9): 980-987. PMID 19705341. [e]